Response to Letter to the Editor from Drs. van Kesteren, Pronk, Heusinkveld, Luijten and Hakkert concerning Yamada et al. (2021): Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR). Crit. Rev. Toxicol. Vol. 51: 373-394.

Tomoya Yamada; Samuel M. Cohen; Brian G. Lake

doi:10.1080/10408444.2022.2101915

Response to Letter to the Editor from Drs. van Kesteren, Pronk, Heusinkveld, Luijten and Hakkert concerning Yamada et al. (2021): Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR). Crit. Rev. Toxicol. Vol. 51: 373-394.

Tomoya Yamada, Samuel M. Cohen, Brian G. Lake

Research output: Contribution to journal › Review article › peer-review

Original language	English (US)
Pages (from-to)	399-402
Number of pages	4
Journal	Critical reviews in toxicology
Volume	52
Issue number	5
DOIs	https://doi.org/10.1080/10408444.2022.2101915
State	Published - 2022

ASJC Scopus subject areas

Toxicology

Access to Document

10.1080/10408444.2022.2101915

Cite this

Yamada, T., Cohen, S. M., & Lake, B. G. (2022). Response to Letter to the Editor from Drs. van Kesteren, Pronk, Heusinkveld, Luijten and Hakkert concerning Yamada et al. (2021): Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR). Crit. Rev. Toxicol. Vol. 51: 373-394. Critical reviews in toxicology, 52(5), 399-402. https://doi.org/10.1080/10408444.2022.2101915

Response to Letter to the Editor from Drs. van Kesteren, Pronk, Heusinkveld, Luijten and Hakkert concerning Yamada et al. (2021): Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR). Crit. Rev. Toxicol. Vol. 51: 373-394. / Yamada, Tomoya; Cohen, Samuel M.; Lake, Brian G.
In: Critical reviews in toxicology, Vol. 52, No. 5, 2022, p. 399-402.

Research output: Contribution to journal › Review article › peer-review

Yamada, T, Cohen, SM & Lake, BG 2022, 'Response to Letter to the Editor from Drs. van Kesteren, Pronk, Heusinkveld, Luijten and Hakkert concerning Yamada et al. (2021): Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR). Crit. Rev. Toxicol. Vol. 51: 373-394.', Critical reviews in toxicology, vol. 52, no. 5, pp. 399-402. https://doi.org/10.1080/10408444.2022.2101915

Yamada T, Cohen SM, Lake BG. Response to Letter to the Editor from Drs. van Kesteren, Pronk, Heusinkveld, Luijten and Hakkert concerning Yamada et al. (2021): Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR). Crit. Rev. Toxicol. Vol. 51: 373-394. Critical reviews in toxicology. 2022;52(5):399-402. doi: 10.1080/10408444.2022.2101915

Yamada, Tomoya ; Cohen, Samuel M. ; Lake, Brian G. / Response to Letter to the Editor from Drs. van Kesteren, Pronk, Heusinkveld, Luijten and Hakkert concerning Yamada et al. (2021) : Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR). Crit. Rev. Toxicol. Vol. 51: 373-394. In: Critical reviews in toxicology. 2022 ; Vol. 52, No. 5. pp. 399-402.

@article{e3de90912d64458fab7bb76300104507,

title = "Response to Letter to the Editor from Drs. van Kesteren, Pronk, Heusinkveld, Luijten and Hakkert concerning Yamada et al. (2021): Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR). Crit. Rev. Toxicol. Vol. 51: 373-394.",

author = "Tomoya Yamada and Cohen, {Samuel M.} and Lake, {Brian G.}",

note = "Funding Information: Dr. Tomoya Yamada is employed by Sumitomo Chemical Company, Ltd. Prof. Samuel M. Cohen and Prof. Brian G. Lake consult for Sumitomo Chemical Company, Ltd. regarding research on CAR activators as well as on other matters. The response was written as part of the authors{\textquoteright} normal employment, but the authors have sole responsibility for the writing and content of this response. The views presented in this response are those of the authors based on many years of research in the respective areas of investigations reported in this response. This work was supported by the Sumitomo Chemical Company, Ltd. ( https://www.sumitomo-chem.co.jp/eng-lish/company/ ). This company is interested in the human relevance of the CAR-mediated MOA for rodent liver tumor formation, because some company products (e.g. pesticides) have CAR activation activity in rodent liver. Some of the research on CAR activators produced by Sumitomo Chemical Company, Ltd. has been utilized by the company in regulatory submissions to provide MOA information for interpreting the relevance to humans of the liver tumors in rodents. None of the authors has appeared in any legal or regulatory proceedings related to the contents of this response. No potential conflict of interest was reported by the authors. Funding Information: The authors thank members of Environmental Health Science Laboratory, Sumitomo Chemical Company, Ltd. for their encouragement to write this response. All authors gave final approval and agreed to be accountable for all aspects of work in ensuring that questions relating to the accuracy or integrity of any part of the work are appropriately investigated and resolved. An additional review of the response for internal approval purposes was conducted by Kyoko Odawara, a Research Director of Environmental Health Science Laboratory, Sumitomo Chemical Company, Ltd., and approved without any changes to what we had written.",

year = "2022",

doi = "10.1080/10408444.2022.2101915",

language = "English (US)",

volume = "52",

pages = "399--402",

journal = "Critical reviews in toxicology",

issn = "1040-8444",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Response to Letter to the Editor from Drs. van Kesteren, Pronk, Heusinkveld, Luijten and Hakkert concerning Yamada et al. (2021)

T2 - Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR). Crit. Rev. Toxicol. Vol. 51: 373-394.

AU - Yamada, Tomoya

AU - Cohen, Samuel M.

AU - Lake, Brian G.

N1 - Funding Information: Dr. Tomoya Yamada is employed by Sumitomo Chemical Company, Ltd. Prof. Samuel M. Cohen and Prof. Brian G. Lake consult for Sumitomo Chemical Company, Ltd. regarding research on CAR activators as well as on other matters. The response was written as part of the authors’ normal employment, but the authors have sole responsibility for the writing and content of this response. The views presented in this response are those of the authors based on many years of research in the respective areas of investigations reported in this response. This work was supported by the Sumitomo Chemical Company, Ltd. ( https://www.sumitomo-chem.co.jp/eng-lish/company/ ). This company is interested in the human relevance of the CAR-mediated MOA for rodent liver tumor formation, because some company products (e.g. pesticides) have CAR activation activity in rodent liver. Some of the research on CAR activators produced by Sumitomo Chemical Company, Ltd. has been utilized by the company in regulatory submissions to provide MOA information for interpreting the relevance to humans of the liver tumors in rodents. None of the authors has appeared in any legal or regulatory proceedings related to the contents of this response. No potential conflict of interest was reported by the authors. Funding Information: The authors thank members of Environmental Health Science Laboratory, Sumitomo Chemical Company, Ltd. for their encouragement to write this response. All authors gave final approval and agreed to be accountable for all aspects of work in ensuring that questions relating to the accuracy or integrity of any part of the work are appropriately investigated and resolved. An additional review of the response for internal approval purposes was conducted by Kyoko Odawara, a Research Director of Environmental Health Science Laboratory, Sumitomo Chemical Company, Ltd., and approved without any changes to what we had written.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85136172224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136172224&partnerID=8YFLogxK

U2 - 10.1080/10408444.2022.2101915

DO - 10.1080/10408444.2022.2101915

M3 - Review article

C2 - 35971811

AN - SCOPUS:85136172224

SN - 1040-8444

VL - 52

SP - 399

EP - 402

JO - Critical reviews in toxicology

JF - Critical reviews in toxicology

IS - 5

ER -

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this